Management of Leg Ulcers in Myelofibrosis Patients
Immediately discontinue hydroxyurea if the patient is receiving it, as leg ulcers represent a criterion for hydroxyurea intolerance in myelofibrosis, and cessation typically leads to spontaneous wound healing. 1
Primary Management Algorithm
Step 1: Identify Hydroxyurea as the Culprit
The presence of leg ulcers in a myelofibrosis patient on hydroxyurea (HU) constitutes an unacceptable non-hematological toxicity and meets formal criteria for HU resistance/intolerance 1. These ulcers have characteristic features:
- Occur after long-term HU treatment at doses ≥1 g/day
- Typically localize to the malleolar region
- Heal spontaneously when HU is discontinued 2
Stop hydroxyurea immediately at any dose if leg ulcers are present - this is explicitly stated in the European LeukemiaNet criteria 1.
Step 2: Switch to Alternative Myelofibrosis Therapy
After stopping hydroxyurea, transition to a JAK inhibitor:
- Ruxolitinib is the preferred alternative - it not only treats the underlying myelofibrosis but has demonstrated efficacy in healing HU-induced leg ulcers that were previously refractory to multiple interventions 3
- Consider momelotinib if the patient has moderate-to-severe anemia 4
- Fedratinib represents another option, though availability varies by region 4
The case report of successful wound healing with ruxolitinib after failed surgical interventions and immunosuppression is particularly compelling 3, suggesting this agent addresses both the underlying disease and the wound pathology.
Step 3: Provide Supportive Wound Care
While awaiting healing after HU discontinuation:
- Ensure adequate compression therapy if venous insufficiency contributes (but only if ankle-brachial index >0.8) 5
- Maintain moist wound environment
- Rule out infection requiring systemic antibiotics
- Verify tetanus immunization status 5
Critical Diagnostic Considerations
Before attributing ulcers solely to hydroxyurea, exclude:
- Arterial insufficiency - check ankle-brachial index
- Venous disease - assess for chronic venous insufficiency
- Vasculitis or cryoglobulinemia - look for typical clinical signs
- Pyoderma gangrenosum - consider if atypical features present 2
However, the distinction between disease-related and treatment-induced ulcers can be difficult and may not always be possible 2. When in doubt, discontinue hydroxyurea and observe for healing - this serves as both diagnostic and therapeutic.
Common Pitfalls to Avoid
- Do not continue hydroxyurea while attempting local wound management - this delays healing and violates established intolerance criteria 1
- Do not assume ulcers are purely vascular without considering HU toxicity - the temporal relationship with HU therapy and malleolar location are key diagnostic clues 2
- Do not delay switching to JAK inhibitor therapy - ruxolitinib provides both disease control and potential wound healing benefits 3
The Evidence Hierarchy
The 2015 ESMO guidelines 1 provide the strongest directive here, explicitly listing leg ulcers as a criterion for HU intolerance requiring treatment change. This is reinforced by clinical research showing spontaneous healing upon HU cessation 2 and successful outcomes with ruxolitinib 3. The pathophysiology remains incompletely understood and likely multifactorial, but the management approach is clear: stop the offending agent and switch to alternative myelofibrosis therapy.